US stem cell clinics, patient safety, and the FDA

Leigh Turner

Research output: Contribution to journalComment/debatepeer-review

50 Scopus citations


Scholarship on patients accessing unproven stem cell interventions is dominated by research addressing 'stem cell tourism' to such countries as China, India, Mexico, and the Ukraine. However, clinics marketing 'adipose-derived mesenchymal stem cell treatments' are proliferating across the USA. These businesses typically claim to operate in compliance with federal regulations, but careful review of their commercial practices suggests that such clinics are marketing unapproved and noncompliant biological drugs.

Original languageEnglish (US)
Pages (from-to)271-273
Number of pages3
JournalTrends in Molecular Medicine
Issue number5
StatePublished - May 1 2015

Bibliographical note

Publisher Copyright:
© 2015 Elsevier Ltd.


  • FDA
  • Federal regulations
  • Marketing
  • Stem cell clinics
  • United States


Dive into the research topics of 'US stem cell clinics, patient safety, and the FDA'. Together they form a unique fingerprint.

Cite this